Evidence map›Paper›PMID 37247330›Full record

ArticleEuropean heart journal2023

SCORE2-Diabetes: 10-year cardiovascular risk estimation in type 2 diabetes in Europe.

SCORE2-Diabetes Working Group and the ESC Cardiovascular Risk Collaboration

3 registry-linked trialsOpen access · hybridAbstract readCase Reports
In one paragraph

Article in European heart journal, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 3 registered trials, which are not on this map. Cited by 168 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
168citing papers in PubMed, 3 pooled it
53.9field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06325800 recruitingnot on this mapstarted 2024, after this paper: background citation

Multimodal Vascular Phenotyping and Target-Organ Damage Using Vascular Imaging, Glyco-Oxidative Biomarkers, and Photoplethysmography in Adults at Increased Cardiovascular Risk: The GlycOxiTOD Observational Registry

Typeobservational_patient_registrySponsorComplejo Hospitalario Universitario de SantiagoRan2024 to 2035Enrolled1,000ConditionsHypertension, Target Organ Damage, Heart Disease Risk Factors, Vascular StiffnessArmsMultimodal Cardiovascular Phenotyping
NCT07602023 recruitingnot on this mapstarted 2024, after this paper: background citation

Triglyceride-rich LIPoproteins and INflammatory Cytokines After Oral FAT Loading as Potential Early Biomarkers of the Risk of Progression Towards DIABETES and Development of Complications. LIPINFAT Diabetes Study.

TypeobservationalSponsorAngelina PassaroRan2024 to 2028Enrolled150ConditionsPrediabetes / Type 2 DiabetesArmsOral Fat Load Test
NCT07695376 recruitingnot on this mapstarted 2026, after this paper: background citation

CArdiovascular Risk Assessment Via Multimodal Data Analysis Enabling Personalised Prevention Strategies Targeting MEnopausaL Women - Observational Study

Typeobservational_patient_registrySponsorBiogipuzkoa Health Research InstituteRan2026 to 2028Enrolled3,000ConditionsPerimenopause, Menopause, Cardiovascular (CV) Risk, Women (Between 30 to 60 Years Old)
3 · Its place in the literature

Who cites it

168 citing papers in PubMed, 3 syntheses or guidelines pooled it, 268 citations in OpenAlex.

  1. Guideline
  2. Pooled it
  3. Guideline
  4. Trial
  5. Trial
  6. Review
  7. Article
  8. Review
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Review
  20. Article

108 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

1 author.

SCORE2-Diabetes Working Group and the ESC Cardiovascular Risk Collaboration

Funding

British Heart Foundation RE/18/1/34212British Heart Foundation RG/13/13/30194British Heart Foundation RG/18/13/33946British Heart Foundation SP/09/002British Heart Foundation SP/18/3/33801Chief Scientist OfficeDepartment of Health BRC-1215–20014Department of Health NIHR203312Medical Research Council MC_UU_00017/3Medical Research Council MR/L003120/1Medical Research Council MR/R007764/1Wellcome Trust
6 · The paper itself

Abstract

aimsTo develop and validate a recalibrated prediction model (SCORE2-Diabetes) to estimate the 10-year risk of cardiovascular disease (CVD) in individuals with type 2 diabetes in Europe. METHODS AND

resultsSCORE2-Diabetes was developed by extending SCORE2 algorithms using individual-participant data from four large-scale datasets comprising 229 460 participants (43 706 CVD events) with type 2 diabetes and without previous CVD. Sex-specific competing risk-adjusted models were used including conventional risk factors (i.e. age, smoking, systolic blood pressure, total, and HDL-cholesterol), as well as diabetes-related variables (i.e. age at diabetes diagnosis, glycated haemoglobin [HbA1c] and creatinine-based estimated glomerular filtration rate [eGFR]). Models were recalibrated to CVD incidence in four European risk regions. External validation included 217 036 further individuals (38 602 CVD events), and showed good discrimination, and improvement over SCORE2 (C-index change from 0.009 to 0.031). Regional calibration was satisfactory. SCORE2-Diabetes risk predictions varied several-fold, depending on individuals' levels of diabetes-related factors. For example, in the moderate-risk region, the estimated 10-year CVD risk was 11% for a 60-year-old man, non-smoker, with type 2 diabetes, average conventional risk factors, HbA1c of 50 mmol/mol, eGFR of 90 mL/min/1.73 m2, and age at diabetes diagnosis of 60 years. By contrast, the estimated risk was 17% in a similar man, with HbA1c of 70 mmol/mol, eGFR of 60 mL/min/1.73 m2, and age at diabetes diagnosis of 50 years. For a woman with the same characteristics, the risk was 8% and 13%, respectively.

conclusionSCORE2-Diabetes, a new algorithm developed, calibrated, and validated to predict 10-year risk of CVD in individuals with type 2 diabetes, enhances identification of individuals at higher risk of developing CVD across Europe.

Indexed as

Cardiovascular DiseasesDiabetes Mellitus, Type 2EuropeFemaleGlycated HemoglobinHeart Disease Risk FactorsHumansMaleMiddle AgedRisk FactorsGlycated HemoglobinCardiovascular diseasesDiabetesPrediction model

Identifiers

PMID37247330
PMCPMC10361012
OpenAlexW4378746292

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.